Chris Bradley, CEO and Co-Founder, Loki Therapeutics talks about a new generation of cancer immune therapy that takes advantage of the body's ability to fight antigens it already recognizes from a previous childhood vaccination. The delivery mechanism uses an attenuated bacteria listeria monocytogenes that colonizes the tumor and triggers the body's immune system through naive T cells. Early data is showing effectiveness for advanced metastatic pancreatic cancer and advanced metastatic ovarian cancer with potential for treating other solid tumors. #LokiTherapeutics #MemoryTCells #immunotherapy #ovariancancer #pancreaticCancer #Cancer LokiTX.com Download the transcript here